Life Science Leader - Home Page
LIFE SCIENCE LEADER CONTENT COLLECTIONS. Adapting With Automation: A Guide For The Modern Lab. Vaccine Maker's Toolkit: Strategies For Manufacturing And Supply Management. Scaling Cell and Gene Therapies. Your Supply Chain On Inflation: An Outsourcing Analysis. Improving Diversity In Clinical Trials.
Where Are They Now? SQZ Biotech - lifescienceleader.com
May 1, 2024 · In 2020, Sharei took SQZ Biotech public with a $71 million IPO, and channeled the funds into its pipeline of novel cell therapies. Being the founder and CEO of SQZ Biotech was Sharei’s first full-time job, and it was “all-consuming,” noted Sharei in the 2019 article. “People often applaud entrepreneurship, lionize its leaders, and paint ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
Dec 3, 2013 · Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
Pharmaceutical Scientists' Salaries in 2023
Jan 15, 2024 · In fact, salaries were up among industry scientists as well as academic scientists (AAPS members) – mean annual base salary from principle, full-time employment in the U.S. as of June 1 (the date of the survey cut off) was $190,100, a 6.7% increase from 2022 ($178,100). Pharmaceutical scientists outside of the U.S. had average base salaries ...
New Leadership At The Cancer Research Institute
Sep 27, 2024 · Dr. Alicia Zhou, Ph.D., the new CEO at the Cancer Research Institute (CRI), aims to bring her experience in academia and the West Coast health tech startup scene to bear on a 70-year-old nonprofit institution with deep roots in cancer immunotherapy. Her experience using Big Data to improve molecular therapeutics, in both the academic and ...
Where Are They Now? Karuna Therapeutics - lifescienceleader.com
Jan 1, 2024 · However, Paul was confident about the drug’s potential success and innovative attributes, a sentiment echoed in the company’s stock price. Now: On December 22, 2023, Bristol Myers Squibb (BMS) announced that it would acquire Karuna Therapeutics, and its promising neuroscience portfolio (including KarXT), in a deal worth $14 billion.
FDA INTERACT Meetings: Early Interactions For Cell And Gene …
Mar 1, 2022 · FDA INTERACT Meetings: Early Interactions For Cell And Gene Therapy Sponsors. By Annette F. Arlinghaus, Director, Regulatory Operations and Stacey A. Ayres, PhD Vice President, Regulatory Strategy. Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well ...
The Future of Anxiety Treatment Will Be Drastically Different
Sep 24, 2020 · More than 40 million Americans are living with an anxiety disorder. If America's youth are a barometer for the future, research suggests the problem is only growing. The rate at which children are diagnosed with anxiety disorders has been steadily increasing, from 5.5% of all children in 2007 to 6.4% of all children by 2011.
About Life Science Leader
Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses. Life Science Leader features interviews ...
Companies To Watch: Antiva Biosciences - Life Science Leader
Feb 27, 2024 · Antiva Biosciences is developing a new drug, coded ABI-2280, for treating Human Papilloma Virus (HPV)-related diseases, including precancerous conditions. ABI-2280 is a prodrug of an acyclic nucleoside phosphonate, formulated to improve safety as well as enhance deliverability as a topical medicine. The drug is now in early to mid-stage ...